Sava raises $36.0M Series B (United Kingdom, Oct 2026)
Reach the investors backing rounds like this
Backed by Ascensia, PHC Holdings · verified emails and LinkedIn on Datapile
Ascensia leads $36M Series B in Sava to replace fingerstick glucose testing - Tech Funding News
Sava is developing a sensor technology aimed at replacing fingerstick glucose testing. The company has secured $36 million in Series B funding, led by Ascensia, to support the commercialization and distribution of its products in Europe. Their goal is to obtain CE approval for insulin dosing without fingerstick checks within 18-24 months.
Ascensia leads $36M Series B in Sava to replace fingerstick glucose testing Tech Funding News
14,847 investors back startups in United Kingdom
You just read who funded Sava. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.